Valeant Pharmaceuticals announces award in Anacor Pharmaceuticals dispute

Posted On 22 Oct 2013
By :

Canada-based Valeant Pharmaceuticals International has announced the interim final award in its previously disclosed arbitration with Anacor Pharmaceuticals to resolve a breach of contract dispute arising out of services provided by Dow Pharmaceutical Sciences, prior to its acquisition by Valeant Pharmaceuticals.


As a result of the September 2013 arbitration hearing, Valeant Pharmaceuticals has been ordered to make a one-time payment of $100m in damages plus costs and fees to Anacor Pharmaceuticals.

The arbitrator did not grant an injunction or ongoing royalty, which means that, while still subject to regulatory approval, nothing in the arbitrator’s order prevents the launch of Jublia (efinaconazole 10% topical solution).

Read the source article at Process & Production Industry News

About the Author

Leave a Reply